Copyright
©The Author(s) 2015.
World J Gastroenterol. Nov 14, 2015; 21(42): 12059-12070
Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.12059
Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.12059
Figure 1 Overview of sorafenib-based combined targeting therapies for hepatocellular carcinoma.
MEK: Mammalian target of rapamycin; ERK: Extracellular-signal regulated kinase; EGFR: Endothelial growth factor receptor; EGF: Epidermal growth factor; HGF: Hepatocyte growth factor.
- Citation: Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12059-12070
- URL: https://www.wjgnet.com/1007-9327/full/v21/i42/12059.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i42.12059